![Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin | Nutrition & Diabetes Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin | Nutrition & Diabetes](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnutd.2014.40/MediaObjects/41387_2014_Article_BFnutd201440_Fig1_HTML.jpg)
Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin | Nutrition & Diabetes
![Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. - Abstract - Europe PMC Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. - Abstract - Europe PMC](https://europepmc.org/articles/PMC4480550/bin/10.1177_2042018815575273-fig1.jpg)
Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. - Abstract - Europe PMC
![Cureus | Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus Cureus | Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus](https://assets.cureus.com/uploads/figure/file/240936/lightbox_7b5ce9c0e87011eba6ca090ee304f44d-fig1.png)
Cureus | Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
![Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali. - ppt download Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali. - ppt download](https://slideplayer.com/slide/13611195/83/images/3/Dapagliflozin+Mechanism+of+Action.jpg)
Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali. - ppt download
![Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors - Ogawa - 2016 - Journal of Diabetes Investigation - Wiley Online Library Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors - Ogawa - 2016 - Journal of Diabetes Investigation - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/022d38be-8a39-4c53-b7ca-723cd3efe1e7/jdi12401-toc-0001-m.jpg)
Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors - Ogawa - 2016 - Journal of Diabetes Investigation - Wiley Online Library
![Mechanism of action of diabetes medications on multiple organ systems:... | Download Scientific Diagram Mechanism of action of diabetes medications on multiple organ systems:... | Download Scientific Diagram](https://www.researchgate.net/publication/339601792/figure/fig1/AS:1084218499174431@1635509242702/Mechanism-of-action-of-diabetes-medications-on-multiple-organ-systems-a-SGLT2_Q320.jpg)
Mechanism of action of diabetes medications on multiple organ systems:... | Download Scientific Diagram
![SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects | Journal of the American Heart Association SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/1cf105b6-6487-4eb9-a303-6500ffa6fd60/jah34382-fig-0002.png)
SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects | Journal of the American Heart Association
![Mechanism of Action (MOA) | FARXIGA® (dapagliflozin) | Diabetes care, Diabetic ketoacidosis, Acute kidney injury Mechanism of Action (MOA) | FARXIGA® (dapagliflozin) | Diabetes care, Diabetic ketoacidosis, Acute kidney injury](https://i.pinimg.com/474x/fd/93/4b/fd934b2bad2314c1eed4261ba341065b.jpg)